BERG is a biopharmaceutical company committed to delivering innovative healthcare solutions through a data-driven approach. BERG is the namesake of Chairman and Co-founder Carl E. Berg, who formed the company together with Co-founders Mitch Gray and Niven R. Narain in 2006.
BERG utilizes AI-based machine learning to infer cause-and-effect relationships in their mission to create next-generation therapeutics and diagnostics. BERG is a clinical-stage company redefining the approach to healthcare through its Interrogative Biology® platform and bAIcis®, their proprietary analytics software.
BERG operates at the intersection of systems biology and AI, processing highly sophisticated patient information to gain actionable insight into human health and disease. BERG is accelerating the understanding of disease profiles, revealing molecular signatures destined to guide and accelerate product candidate selection and development.
BERG has leveraged its Interrogative Biology® platform and traditional R&D methods to develop a robust pipeline of therapeutic product candidates and diagnostic technologies in oncology, neurology, and rare diseases.
BERG’s leading drug candidate is BPM31510. BPM31510 has shown promise in early phase trials, with orphan drug status being granted in 2018 for the treatment of pancreatic cancer. Further trials are planned in a number of different cancer types.